San Francisco-based drug company Portola Pharmaceuticals has taken a $60 million extension to its third round of funding to see it through Phase II trials for betrixaban, a drug intended to prevent blood clots. The company is also working on an antiplatelet agent called PRT060128. If its drugs do well in trials, the company will likely head to an IPO, as we reported alongside its last $70 million fundung.

Managing Application Performance by Understanding Applications Learn more, download free white paper.

The Compelling ROI Benefits of Contact Center Quality and Performance Management Technologies. Learn more, download free white paper.

Xceed Contact Center – Diversifying on Existing Strengths Learn more, download free white paper.

Disaster Recovery and Your Voice Messaging Learn more, download free white paper.

Voice Peering: Reduce time to market and risk. Learn more, download free white paper.

Business Process Improvement - Dramatically enhance business performance with IP communications Learn more, download free white paper.

In all, Portola has taken about $200 million to date. A large set of investors came on for the funding. New investor D.E. Shaw & Co. led, and was joined by other newcomers Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and Pac-Link BioVentures. The existing investors participating included: Abingworth, Advanced Technology Ventures, AllianceBernstein LP, Alta Partners, Brookside Capital, China Investment & Development Co., Frazier Healthcare, Goldman Sachs, IBT Management Corp., MPM Capital, Prospect Ventures, Sutter Hill Ventures, and Teachers' Private Capital.